Published: August 14, 2018

Introduction {#sec1}
============

Dendritic cells (DCs) are a heterogeneous family of rare antigen-presenting cells, which sense danger signals and convey them to lymphocytes for the orchestration of adaptive immunity. Although widely used, immunotherapies using human-monocyte-derived DCs (MoDCs) showed limited efficacy due to poor recirculation of MoDCs to lymph nodes ([@bib1], [@bib35]) and other differences with lymphoid tissue-resident DCs (LT-DCs) ([@bib6]). Hence, efforts are ongoing to better characterize human LT-DCs ([@bib17], [@bib43], [@bib50], [@bib51]).

Human LT-DCs encompass three major cell types: CD141(BDCA3)^+^CLEC9A^+^ classical DCs (cDC1s), CD1c(BDCA1)^+^ classical DCs (cDC2s), and CLEC4C(BDCA2)^+^ CD123^+^ plasmacytoid DCs (pDCs) ([@bib54]). Human and mouse LT-DCs are homologous, based on comparative transcriptomics and functional studies ([@bib36], [@bib51]). Human and mouse cDC1s excel in cross-presentation of cell-associated antigens, as well as of particulate antigen when delivered in combination with polyinosinic-polycytidylic acid (poly(I:C)) stimulation or to lysosomes through Fcγ receptors ([@bib51]). cDC1s express XCR1, a chemokine receptor whose ligands are mostly produced by natural killer and CD8^+^ T cells ([@bib51]). They also strongly express Toll-like receptor 3 (TLR3), which induces high levels of interferon λ (IFN-λ) when triggered by poly(I:C) or certain viruses and enhances cross-presentation ([@bib51]). Hence, cDC1s are key candidate cells for the development of innovative immunotherapies against cancer or chronic infections by intracellular pathogens ([@bib40]). Committed cDC precursors (pre-cDCs) giving rise only to cDC1s or cDC2s exist in both mice and humans and can be mobilized *in vivo* using FLT3L ([@bib8], [@bib9], [@bib26], [@bib29], [@bib41], [@bib43]). Nevertheless, the mechanisms controlling human cDC1 development and functions are not well understood, which hampers their clinical targeting.

pDCs are prominent producers of type I (α/β) and III (λ) IFNs, which mediate potent antiviral effects ([@bib48]) and can promote protective immunity to cancer ([@bib40]). Favorable immune responses were observed in melanoma patients treated by adoptive transfer of autologous pDCs loaded *ex vivo* with antigen and matured with an attenuated virus vaccine ([@bib46]). The crosstalk between cDC1s and pDCs promotes the induction of optimal, protective, adaptive immune responses to viral infections and cancer in mice ([@bib20], [@bib33], [@bib53]) and likely in humans as well ([@bib44]). Hence, targeting cDC1s and their crosstalk with pDCs for the design of innovative immunotherapies is very promising.

DCs are rare cells in blood and most tissues, which complicates not only their clinical application, including for adoptive transfer immunotherapy against cancers ([@bib7]), but also basic studies aiming at deciphering their biology. This problem could be solved by developing methods to generate all three DC types *in vitro* from cultures of hematopoietic stem cells ([@bib26], [@bib47]). However, further studies are required to rigorously demonstrate the identity of *in vitro* CD34^+^ stem cell-derived DC types and the extent of their homology to their blood counterparts ([@bib50]). Moreover, yields were very low in these studies, emphasizing an unmet need to further develop optimal protocols to generate these cells *in vitro* in larger numbers and enable their manipulation. The present study was designed to overcome this bottleneck.

Results {#sec2}
=======

Development of an *In Vitro* Culture System to Differentiate Large Numbers of Human cDC1s and pDCs {#sec2.1}
--------------------------------------------------------------------------------------------------

Human pDCs can develop from CD34^+^ progenitors cultured on OP9 stromal cells with FLT3L and interleukin-7 (IL-7). Contradictory results were reported on the role of Notch signaling in this process ([@bib13], [@bib34]). The differentiation of cDC1s was not examined in these culture systems. Thus, we investigated whether OP9 stromal cells allow simultaneous differentiation of both pDCs and cDC1s from human CD34^+^ cord blood (CB) progenitors and whether Notch signaling affects this process. We developed an *in vitro* model of human DC differentiation ([Figure 1](#fig1){ref-type="fig"}A). It was built by combining two previously published protocols, ours for cDC1 generation in the absence of a feeder layer ([@bib6]) with one using OP9 stromal cells for pDC development ([@bib13]), with additional key adaptations. Specifically, CD34^+^ CB cells were first expanded with FLT3L, SCF, TPO, and IL-7 (FST7) for 7 days. Cells were then differentiated with FLT3L, TPO, and IL-7 (FT7) on OP9 stromal cells expressing or not the Notch ligand Delta-like 1 (DLL1) or on a combination of these cells (OP9+OP9_DLL1) for 18--21 days ([Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}A). At the end of the culture, pDCs and cDC1s were identified by flow cytometry ([Figure 1](#fig1){ref-type="fig"}B). OP9 cells allowed efficient generation of pDCs, consistent with an earlier report ([@bib13]). This culture condition yielded only very low frequencies of cDC1s ([Figures 1](#fig1){ref-type="fig"}B and 1C). In contrast, in the presence of OP9_DLL1, a much higher frequency of cDC1s was found (7.8% ± 5.3 versus 0.3% ± 0.3; p = 0.03), with significantly lower pDC frequencies (8.4% ± 9.3 versus 17.4% ± 7.4; p = 0.03) ([Figures 1](#fig1){ref-type="fig"}B and 1C). Differentiating the expanded CD34^+^ CB precursors on a mixed (OP9+OP9_DLL1) feeder layer yielded maximal frequencies for both DC types within the same culture ([Figures 1](#fig1){ref-type="fig"}B and 1C). Large numbers of cells were generated on OP9+OP9_DLL1 for both cDC1s and pDCs, whereas this was the case on OP9_DLL1 only for the former population and on OP9 only for the latter ([Figure 1](#fig1){ref-type="fig"}D). On a mixed OP9+OP9_DLL1 feeder layer, 10^4^ expanded input cells yielded 1.1 ± 0.62 × 10^5^ cDC1s and 4.1 ± 2.12 × 10^5^ pDCs ([Figure 1](#fig1){ref-type="fig"}D). FLT3L was critical for cDC1 generation and strongly synergized with IL-7 and TPO to increase yields of both DC types ([Figures S1](#mmc1){ref-type="supplementary-material"}B--S1E). Recently, the CD123^+^ BDCA2^+^ gate commonly used to identify blood pDCs was shown to encompass a newly identified population of AXL^+^SIGLEC6^+^ DCs that failed to produce type I/III IFNs and was proposed to account for the T cell-activating functions previously attributed to pDCs ([@bib43], [@bib50]). Our FT7 cultures contained a very low frequency of these cells ([Figure S2](#mmc1){ref-type="supplementary-material"}). Since CD34^+^ CB cell numbers increased 2.9-fold ± 1.4-fold under FST7 expansion conditions, our culture system on OP9+OP9_DLL1 gave cDC1 and pDC yields 3 to 20 times higher than those previously reported ([@bib26], [@bib47]) ([Table S1](#mmc1){ref-type="supplementary-material"}). In addition, it identified DLL1-dependent Notch signaling as a critical factor to promote cDC1 differentiation *in vitro*.Figure 1pDCs and cDC1s Can Be Efficiently Generated from Human CD34^+^ Cord Blood Cells(A) CD34^+^ cord blood (CB) cells were expanded with FLT3L, SCF, TPO, and IL-7 (FST7) for 7 days. Subsequently, they were differentiated on OP9, OP9_DLL1, or OP9+OP9_DLL1 feeder layer cells, with FLT3L, TPO, and IL-7 (FT7), for 14--21 days.(B) On day 18 of differentiation, within the live-cell gate, pDCs were identified as CD206^−^CD14^−^CD123^+^BDCA2^+^ cells and cDC1s as CD206^−^CD14^−^CLEC9A^+^ cells positive for BDCA3 or CADM1. Plots show one experiment using CB204 donor CD34^+^ cells for parallel differentiation on the 3 feeder layers. Data are representative of 5 experiments each performed with cells from one or two different donors. Pie charts show mean percentage of pDCs or cDC1s within the live-cell gate from the 5 experiments.(C and D) Frequencies (C) and numbers per well (i.e., per 10^4^ expanded CD34^+^ cells) (D) of cDC1s (top) and pDCs (bottom) among total live cells on day 18 after differentiation on the 3 different feeder layers. Graphs show individual results for each of the 6 donors.See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.

Inhibition of Notch Signaling Blocks cDC1 Development *In Vitro* {#sec2.2}
----------------------------------------------------------------

To further evaluate the dependence of cDC1 development on Notch signaling, we assessed the effect of treating our cultures with N-\[N-(3,5-difluorophenacetyl)- L-alanyl\]-S-phenylglycine t-butyl ester (DAPT). This inhibitor blocks the γ-secretase, an enzyme required for Notch activation downstream of its engagement by its ligands. When FT7 cultures were treated with DAPT weekly during the differentiation phase ([Figure 2](#fig2){ref-type="fig"}A), both cDC1 frequency and numbers dropped dramatically, whereas pDC frequency and numbers remained high ([Figures 2](#fig2){ref-type="fig"}B--2D). To assess when during differentiation Notch signaling is required the most, we added DAPT at different time points ([Figure 3](#fig3){ref-type="fig"}A). The inhibition of cDC1 development by DAPT was particularly strong when it was added at the beginning of differentiation (w1 or w1+2). Delayed treatment had a much lower (w2+3) or even no (w3) impact ([Figures 3](#fig3){ref-type="fig"}B and 3C). By contrast, pDC development was rather increased upon DAPT addition to the cultures ([Figures 3](#fig3){ref-type="fig"}B and 3C). Hence, in our culture system, Notch signaling is required at early time points for efficient *in vitro* differentiation of cDC1s, whereas it can inhibit pDC development.Figure 2cDC1s Develop from Human CD34^+^ CB Cells Dependent on Notch Signaling(A) Expanded CD34^+^ CB cells were differentiated with FT7 on OP9_DLL1 feeder layer cells in the presence or absence of DAPT or DMSO.(B) Plots show one experiment using CB204 donor CD34^+^ cells. Data are representative of 5 experiments each performed with cells from 1--3 different donors. Pie charts show mean percentage of pDCs or cDC1s within the live-cell gate from the 8 donors on day 18--21 of differentiation.(C and D) Frequency (C) and numbers per well (D) of cDC1s (top) and pDCs (bottom) among total live cells. Graphs show individual results for each of the 8 donors.Figure 3Notch Signaling Impacts cDC1 Differentiation from Human CD34^+^ CB Cells Early During Development(A) Experimental setup. Medium (untreated), DAPT, or DMSO was added on one or several days during differentiation to define when DAPT inhibits cDC1 development.(B) Frequency of cDC1s (left) and pDCs (right) among total live cells after DMSO or DAPT treatment. Data from triplicate wells of one donor representative of 5 tested are depicted.(C) Numbers of live cDC1s (left) and pDCs (right) after DMSO or DAPT treatment. Numbers are normalized to DMSO and represent mean values of triplicate wells for 3 donors from one experiment representative of two. The mean ± SD across the three donors is shown for each experimental condition. Statistics were performed using the Student's paired t test.

*In-Vitro*-Generated pDCs and cDC1s Share Key Functional Characteristics with Their *In Vivo* Equivalents {#sec2.3}
---------------------------------------------------------------------------------------------------------

To characterize *in vitro* generated pDCs and cDC1s functionally, we assessed their activation upon stimulation with synthetic TLR agonists. All TLR agonists tested increased cDC1 expression of HLA-DR, CD80, CD83, and CD86 ([Figure 4](#fig4){ref-type="fig"}A). By contrast, pDCs mainly upregulated HLA-DR, CD80, and CD86 upon TLR7 stimulation (R848 or R848+poly(I:C)) and CD83 upon TLR9 stimulation (CpG2216) ([Figure 4](#fig4){ref-type="fig"}A). A high proportion of *in-vitro*-derived cDC1s produced IFN-λ, but not IFN-α, specifically upon TLR3 triggering (poly(I:C) or R848+poly(I:C)) ([Figure 4](#fig4){ref-type="fig"}B). IL-12 was induced strongly only in cDC1s, specifically upon TLR8 triggering (R848 or R848+poly(I:C)) ([Figure 4](#fig4){ref-type="fig"}C). Tumor necrosis factor (TNF) production was induced in cDC1s both by TLR3 and TLR8 activation and very weakly by TLR4, but not by TLR9, activation ([Figure 4](#fig4){ref-type="fig"}C). In the same cultures, pDCs expressed cytokines only upon TLR7 or TLR9 triggering, with a high induction of IFN-α and TNF and a milder expression of IFN-λ than cDC1s ([Figures 4](#fig4){ref-type="fig"}B and 4C). Hence, *in-vitro*-generated pDCs and cDC1s harbored the same responses to TLR triggering than previously described for their *in vivo* counterparts ([@bib6], [@bib18], [@bib19], [@bib21], [@bib25], [@bib31]).Figure 4pDCs and cDC1s Generated from Human CD34^+^ CB Cells Share Key Functional Characteristics with Their Blood CounterpartsOP9+OP9_DLL1 FT7 cultures were stimulated with the indicated agonists. cDC1s were gated as live CD14^−^CD206^−^CD123^neg-to-low^BDCA2^−^CADM1^+^ cells and pDCs as CD14^−^CD206^−^CD123^+^BDCA2^+^ cells. Plots are representative of 4 donors from 2 experiments.(A) Activation marker expression.(B) Intracellular expression of IFN-α/λ.(C) Intracellular expression of IL-12p40 and TNF.

*In-Vitro*-Generated pDCs and cDC1s Share Key Phenotypic Characteristics with Their *In Vivo* Equivalents {#sec2.4}
---------------------------------------------------------------------------------------------------------

We analyzed our cultures for cell-surface expression of classical DC type markers. For a more unbiased flow cytometry data analysis, we used viSNE applied to all live Lineage (Lin)^−^ HLA-DR^+^ cells. This algorithm takes into consideration all the parameters analyzed to regroup cells harboring similar expression patterns close together on a two-dimensional plot ([@bib2]). This approach identified two clusters matching the phenotypes of blood cDC1s and pDCs, respectively, namely CD34^−^ CX3CR1^−^ SIRPα^−^ BDCA2^low/−^ CADM1^+^ BTLA^+^ CLEC9A^+^ CD1c^+^ versus CD34^−^ CX3CR1^low/--^ CADM1^−^ CLEC9A^−^ CD1c^−^ BTLA^+^ ILT7^+^ BDCA2^+^ CD123^+^ cells ([Figures 5](#fig5){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A). *In-vitro*-derived cDC1s expressed CD1c, contrary to blood cDC1s but consistent with cDC1s isolated from FLT3L-injected human volunteers or differentiated *in vitro* from CD34^+^ CB cells with FLT3L on MS5 feeder cells ([@bib8], [@bib26]). In our cultures, some CD34^−^ CADM1^−^ cells co-expressed CD1c, SIRPα and CX3CR1, putatively encompassing pre-cDC2 (BTLA^+^) or cDC2 (BTLA^−^) ([Figure 5](#fig5){ref-type="fig"}A) ([@bib43]). Overlaying the viSNE plot with manual gates for pDCs, cDC1s, CD1c^+^ BTLA^+^ and CD1c^+^ CX3CR1^+^ BTLA^−^ cells, confirmed the localization of these cell populations in the expected areas of the viSNE plot ([Figures 5](#fig5){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}B). In summary, in our culture system, we identified pDCs and cDC1s that share key phenotypic characteristics with their blood equivalents.Figure 5Flow Cytometric and scRNAseq Analyses Confirm the Identity of the pDCs and cDC1s Generated from Human CD34^+^ CB Cells and Identify Heterogeneity within cDC1s(A) viSNE plots from live Lin^−^HLA-DR^+^ cells harvested from 18 day OP9+OP9_DLL1 FT7 cultures. Color codes indicate relative levels of marker cell-surface expression.(B) Overlay of the viSNE plot shown in (A) with the manually gated populations indicated in the legend. pDCs were gated as BDCA2^+^CD123^+^ and cDC1s as BDCA2^−^CD123^neg-to-low^CADM1^+^CD1c^+^. In the remaining CADM1^−^ cells, CD1c^+^ cells were subdivided into BTLA^−^CX3CR1^+^ and BTLA^+^ cells. Plots are representative of 4 donors from 2 experiments.(C) Lineage^−^HLA-DR^+^ single cells were index sorted for phenotypes of cDC1s (CD141^+^CADM1^+^), pDCs (CADM1^−^CD123^+^BDCA2^+^), putative pre-cDC2s (CADM1^−^BDCA2^−^CD1c^+^BTLA^+^), or putative cDC2s (CADM1^−^BDCA2^−^CD1c^+^BTLA^−^), as indicated by the symbols in the graphical legend. scRNAseq was performed using the SmartSeq2 protocol, followed by unsupervised dimensional reduction of the data using t-distributed stochastic neighbor embedding (t-SNE) with graph-based clustering. 7 cell clusters were identified as indicated by the color code in the graphical legend.(D) Violin plots showing mRNA expression profiles of previously known MNP-type-specific genes across all individual cells and in comparison between clusters identified in (A).(E) Enrichment analyses performed on each cell using connectivity map (cMAP), with independently generated and previously published human MNP-type-specific transcriptomic fingerprints. Results are presented as violin plots showing cell densities for the different cMAP scores (y axis) across the cell clusters (x axis) identified in (A). cMAP scores close to 1 versus −1 indicate strong enrichment of the signature of the cell type labeled on top versus bottom of the y axis.(F) Violin plots showing expression profiles of differentially expressed genes between clusters 6 and 7 (cDC1s).Individual dots represent single cells (C, D, and F). Data in (C)--(F) represent one experiment using one donor.(G) Protein expression of CLEC9A and CXCR4 on Lin^−^HLA-DR^+^CADM1^+^BDCA2^−^XCR1^−^ and XCR1^+^ cDC1s from FT7 cultures analyzed by flow cytometry. Plots are representative of 3 experiments and 5 donors.(H) Protein expression of CLEC9A and XCR1 on Lin^−^HLA-DR^+^CD11c^+^ CD1c^−^CADM1^+^ cDC1s from adult peripheral blood analyzed by flow cytometry. Plots are representative of 3 experiments encompassing 6 different donors.(I) XCR1 protein expression on adult peripheral blood cDC1s sorted as Lin^−^HLA-DR^+^CD11c^+^CD1c^−^CD141^+^CADM1^+^CLEC9A^+^ and either XCR1^+^ or XCR1^−^ 14 days after *in vitro* culture on OP9-DLL1 cells with the FT7+G cytokine cocktail. One experiment representative of three is shown. Dotted line, fluorescent minus one control; plain line, XCR1 staining.(J) Expansion of the sorted XCR1^−^ subset of adult peripheral blood cDC1s after 14 days of *in vitro* culture on OP9-DLL1 cells with the FT7 cytokine cocktail supplemented with GM-CSF (1 ng/mL). Data shown are from 3 experiments, each with a different donor (symbols), with mean ± Sd shown across the three donors for each experimental condition.See also [Figures S3--S6](#mmc1){ref-type="supplementary-material"} and [Data S1](#mmc2){ref-type="supplementary-material"}.

Single-Cell RNA Sequencing Demonstrates a Strong Homology between *In-Vitro*-Derived cDC1s and pDCs and Their Blood Counterparts and Unravels an Overlooked Heterogeneity within cDC1s {#sec2.5}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We next performed SmartSeq2 single-cell RNA sequencing (scRNAseq) of selected, index-sorted cell populations from our *in vitro* cultures in order to further evaluate the extent of their homology to blood DC types and assess the degree of homogeneity within each population. Unlike bulk transcriptomics, scRNAseq allows rigorously assessing the lack of contamination of any flow cytometry gated cell population by other cell types and also enables distinguishing in an unbiased way different cell states for a given cell type ([@bib49]). Single live Lin^−^ HLA-DR^+^ cells were sorted from OP9+OP9_DLL1 FT7 cultures. pDCs were sorted as CD141^low/−^ CADM1^−^ BDCA2^+^ CD123^+^ cells and cDC1s as CD141^+^ CADM1^+^ cells ([Figure S3](#mmc1){ref-type="supplementary-material"}). We also included the putative pre-cDC2s (CD1c^+^ BTLA^+^) and cDC2s (CD1c^+^ CX3CR1^+^) that we had identified ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C). Unsupervised dimensional reduction and graph-based clustering of the data identified 7 cell clusters based only on gene expression profiling ([Figure 5](#fig5){ref-type="fig"}C).

Cluster 4 contained only (and the majority of) sorted putative pDCs (13 out of 15). Many genes known to be selectively expressed in pDCs ([@bib36]) were specifically expressed to high levels in cluster 4. These genes encompassed *GZMB*, *PTCRA*, *SPIB*, *LILRA4*, *CLEC4C*, *TCF4*, *IL3RA*, *IRF7*, *TLR7*, and *PLAC8* ([Figures 5](#fig5){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}). A connectivity map (cMAP) analysis was performed on each single cell, using human mononuclear phagocyte (MNP)-type-specific transcriptomic fingerprints generated from previous, independent microarray data ([@bib11], [@bib36]). For cluster 4, cMAP scores were enriched for pDC, but not cDC1 or cDC2, genes ([Figure 5](#fig5){ref-type="fig"}E). Lymphoid genes were also enriched in cluster 4, consistently with pDC ontogeny ([@bib38]) and with their known high expression of B cell-related transcripts ([@bib10], [@bib50]).

Clusters 6 and 7 contained exclusively all the cells sorted as putative cDC1s ([Figure 5](#fig5){ref-type="fig"}C). The genes highly expressed selectively in these two clusters encompassed many genes known to be cDC1 specific ([@bib36]), including *CADM1*, *CLEC9A*, *IDO1*, *C1orf54*, *BATF3*, *SLAMF8*, *SNX22*, *CPNE3*, *GCSAM*, *THBD*, and *CLNK* ([Figures 5](#fig5){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}). cMAP analysis also identified exclusively for clusters 6 and 7 an enrichment for cDC1 transcriptomic fingerprints ([@bib11], [@bib36]) ([Figure 5](#fig5){ref-type="fig"}E). Hence, scRNAseq demonstrated a strong homology between *in-vitro*-derived pDCs or cDC1s and their *in vivo* counterparts.

The identity of the cells sorted as putative pre-cDC2s or cDC2s remained elusive. Whereas most of the cells of these respective phenotypes constituted cluster 1 versus 3 and 5, respectively, some combined together in cluster 2. Hence, our phenotypic CD1c^+^BTLA^+/−^ key did not clearly segregate distinct MNP types. Moreover, putative cDC2s from clusters 3 and 5 selectively expressed high levels of not only *CLEC10A* and *FCER1A*, the hallmark blood cDC2 genes ([@bib17], [@bib43], [@bib50]), but also *OSCAR* and *MRC1* (CD206), genes considered as more associated with monocytes or macrophages ([Figure 5](#fig5){ref-type="fig"}D). Consistently, the cMAP scores of cell clusters 3 and 5 were high for the cDC2 versus cDC1 signature but low for the cDC2 versus monocyte and macrophage signature ([Figure 5](#fig5){ref-type="fig"}E). Hence, whether our FT7 cultures contain cDC2 equivalents remained unclear based on these data.

Surprisingly, scRNAseq analysis unraveled an overlooked heterogeneity within *in-vitro*-derived cDC1s. Indeed, cDC1 clusters 6 and 7 showed reciprocal expression of *XCR1* and *CLEC7A* versus *CXCR4*, *CLEC12A*, and genes associated with cell proliferation ([Figures 5](#fig5){ref-type="fig"}F and [S4](#mmc1){ref-type="supplementary-material"}). Flow cytometry analysis of *in-vitro*-derived CLEC9A^+^CADM1^+^ cDC1s confirmed a reciprocal expression of XCR1 and CXCR4 on these cells ([Figure 5](#fig5){ref-type="fig"}G). Re-analysis of an independent, public scRNAseq dataset encompassing *in-vitro*-derived cDC1s differentiated from CD34^int^CD100^+^ progenitors on MS5 stromal cells ([@bib50]) confirmed the existence of a fraction of cDC1s expressing higher levels of *CXCR4*, *CLEC12A*, and mitosis genes than the remaining cDC1s ([Figure S5](#mmc1){ref-type="supplementary-material"}). Hence, independently and in two systems of *in vitro* differentiation of CD34^+^ progenitors, two distinct cDC1 states were identified: terminally differentiated XCR1^+^ cells and their likely immediate precursors harboring a transcriptomic signature associated with mitosis.

Notch signaling did not promote cDC1 expression of XCR1, since it was not required for induction of this receptor on XCR1^−^ cDC1s sorted from CD34^+^ cell cultures and replated on an OP9_DLL1 feeder layer ([Figure S5](#mmc1){ref-type="supplementary-material"}B), and the frequencies of XCR1^+^ cells in cDC1s in the CD34^+^ cell cultures were not higher on OP9_DLL1 than on OP9 feeder cells ([Figure S6](#mmc1){ref-type="supplementary-material"}C).

Blood CADM1^+^CLEC9A^+^ cDC1s also encompassed XCR1^+^ and XCR1^−^ cells ([Figures 5](#fig5){ref-type="fig"}H and [S6](#mmc1){ref-type="supplementary-material"}A). We sorted both fractions ([Figure S6](#mmc1){ref-type="supplementary-material"}B) and cultured them for 14 days on OP9_DLL1 feeder layers with FT7 in the presence of GM-CSF that was crucial to preserve cellular viability (FT7+G). Upon *in vitro* culture, the XCR1^−^ subset of peripheral blood cDC1s acquired XCR1 expression ([Figure 5](#fig5){ref-type="fig"}I) and expanded ([Figure 5](#fig5){ref-type="fig"}J). Hence, peripheral blood cDC1s encompass an XCR1^−^ fraction that can proliferate and acquire XCR1 expression, suggesting that these cells are *in vivo* equivalents of the immediate precursors of the XCR1^+^ cDC1s identified in our *in vitro* differentiation system.

GM-CSF Boosts cDC1 Differentiation, Allowing Their Efficient Generation from Non-mobilized Adult Blood CD34^+^ Precursors {#sec2.6}
-------------------------------------------------------------------------------------------------------------------------

Since GM-CSF is known to promote cDC differentiation and survival, we tested whether adding it to FT7 cultures further improved cDC1 yields. Adding GM-CSF at the beginning of differentiation (day 0 or 7) increased cDC1 frequencies and numbers ([Figures 6](#fig6){ref-type="fig"}A and 6B) without significantly affecting pDC differentiation ([Figures 6](#fig6){ref-type="fig"}A and 6C). Specifically, GM-CSF enhanced cell proliferation during the initial phase of differentiation ([Figures 6](#fig6){ref-type="fig"}D and 6E) rather than protecting DCs from cell death ([Figure 6](#fig6){ref-type="fig"}F). Moreover, the addition of GM-CSF to OP9_DLL1 FT7 cultures significantly increased the frequency of XCR1^+^ cells within cDC1s ([Figure 6](#fig6){ref-type="fig"}G). These results are consistent with the expansion and acquisition of XCR1 expression by *ex-vivo*-isolated peripheral blood XCR1^−^ cDC1s upon *in vitro* culture with FT7+G on OP9_DLL1 feeder layers ([Figures 5](#fig5){ref-type="fig"}I and 5J). Importantly, our optimized protocol combining the OP9+OP9_DLL1 feeder with the FT7+G cytokine differentiation cocktail allowed efficient generation of both pDCs and cDC1s from non-mobilized adult blood CD34^+^ precursors ([Figure 6](#fig6){ref-type="fig"}H). This is particularly relevant for therapeutic applications, since the use of autologous cells is preferable ([@bib37]).Figure 6GM-CSF Promotes cDC1 Differentiation from CB and Non-mobilized Adult Blood CD34^+^ Cells(A--C) Expanded CD34^+^ CB cells were differentiated with FT7 on OP9_DLL1 feeder layer cells in the absence or presence of GM-CSF added at different time points.(A) Top: frequencies of live CD123^+^ and CD141^+^ cells in the CD14^−^CD206^−^ gate. Bottom: frequencies of CD141^+^CLEC9A^−^ and CD141^+^CLEC9A^+^ cells within the CD141^+^ gate shown on the top. Plots are from one donor (representative of 4). FT7+G, 1 ng/mL GM-CSF added to FT7 on days 0, 7, and 14 of differentiation.(B and C) Frequencies (top) and absolute numbers (bottom) of cDC1s (B) and pDCs (C) generated in the absence or presence of GM-CSF added at the indicated concentrations on days 0, 7, and 14 (w1--3), 7 and 14 (w2--3), or 14 (w3) of differentiation. Absolute numbers of cells obtained were calculated for an initial input of 10^4^ CD34^+^ CB cells, taking into consideration both the expansion and differentiation phases. Data shown are from 4 experiments, each with a different donor (symbols), with mean ± SD shown across donors for each experimental condition. Statistics were performed comparing each condition of GM-CSF supplementation with the FT7 control culture.(D) Carboxyfluorescein diacetate succinimidyl ester (CFSE)-stained cells were differentiated with FT7 or FT7+G (0.25 ng/mL) and harvested over time to measure cell expansion. Each symbol represents an individual donor (D1, D2, and D3). The open versus closed formats represent different days of harvest (day \[d\]6, d12, and d18).(E) Mean CFSE fluorescent intensity at days 6 and 12 on total cells in the same differentiation cultures as shown in (D).(F) Fraction of live (PI^−^Annexin-V^−^) versus early apoptotic (PI^−^Annexin-V^+^), late apoptotic (PI^+^Annexin-V^+^), or necrotic (PI^+^Annexin-V^−/low^) cells in cultures over time, for the individual donors (symbols), which mean ±SD shown across donors for each day.(G) Frequency of XCR1^−^ versus XCR1^+^ cells in the cDC1s generated *in vitro* from FST7-expanded CB CD34^+^ cells differentiated for 18 days on OP9_DLL1 feeders with FT7 or FT7+G. Data shown are from 2 experiments, each with 1--3 different donors (symbols), with mean ± SD shown across donors for each experimental condition.(H) Frequency (top) and total numbers (bottom) of CD123^+^CD45RA^+^ pDCs and CD141^+^CLEC9A^+^ cDC1s generated from 10^4^ non-mobilized FST7-expanded CD34^+^ cell from adult peripheral blood differentiated on OP9+OP9_DLL1 feeder with FT7 or FT7+G. Data shown are from 3 experiments, each with 2 different donors (6 data points with their mena ± SD shown for each condition).

Unbiased, High-Throughput, scRNAseq Analysis of the OP9+OP9_DLL1 FT7 Culture Broadens Identification of DC Types and Differentiation States {#sec2.7}
-------------------------------------------------------------------------------------------------------------------------------------------

To further characterize the cellular composition of our OP9+OP9_DLL1 FT7 cultures, we performed scRNAseq experiments using the 10X Genomics droplet system, enabling a higher throughput and bypassing the need for enrichment of rare cell types or states through the use of biased phenotypic keys ([Figure 7](#fig7){ref-type="fig"}). At day 19 of differentiation, bulk hematopoietic (CD45^+^) live cells were sorted and used for scRNAseq, leading to a detection of 2,563 single cells in 12 clusters ([Figure 7](#fig7){ref-type="fig"}A). Cell cluster identity was inferred by systematic high-throughput gene set enrichment analyses (GSEA) using transcriptomic signatures established independently from microarray analyses ([@bib52]) or from scRNAseq profiling of Lin^−^HLA-DR^+^ peripheral blood mononuclear cells (PBMCs; [Figure S7](#mmc1){ref-type="supplementary-material"}; [Data S1](#mmc2){ref-type="supplementary-material"}). This approach identified two clusters of pDCs (C1 and C11), one cluster of cDC1s (C7), one cluster of cDC2s (C4), and one cluster of monocyte-derived cells (C10). The smallest pDC cluster (C11) expressed cell-cycle genes ([Figures 7](#fig7){ref-type="fig"}B and 7E), likely representing pre-terminally differentiated pDCs. The most prominent cell cluster (C0) and a smaller one (C8) were not strongly enriched in lymphoid or myeloid transcriptomic signatures ([Figures S7](#mmc1){ref-type="supplementary-material"}, [7](#fig7){ref-type="fig"}B, and 7E) or cell-cycle genes ([Figures 7](#fig7){ref-type="fig"}B and 7E), likely representing multipotent hematopoietic progenitors in consistency with high CD34 expression by C0 cells ([Figure 7](#fig7){ref-type="fig"}E). Three cell clusters (C2, C3, and C5) were enriched in lymphoid gene signatures ([Figures S7](#mmc1){ref-type="supplementary-material"}, [7B, and 7](#fig7){ref-type="fig"}E), with C5 expressing cell-cycle genes ([Figures 7](#fig7){ref-type="fig"}B and 7E). These cells are likely hematopoietic progenitors committed to lymphoid differentiation, since no differentiated lymphocytes were detected in our cultures (\<0.1% of cells were positive for lymphoid lineage markers). Cluster C9 harbored high levels of genes selectively co-expressed in pro-myelocytes, myeloid progenitors, or neutrophils ([@bib28]) (<http://biogps.org/dataset/BDS_00013/primary-cell-atlas/>). Cluster C6 belonged to the myeloid lineage ([Figure S7](#mmc1){ref-type="supplementary-material"}), but its precise identity remained ambiguous. Whereas this analysis uncovered a cluster of mitosis-gene-expressing pre-pDCs, it did not identify any clear heterogeneity in the cDC1 population, contrary to our SmartSeq2 experiment. Hence, to better characterize the heterogeneity of MNPs in our OP9+OP9_DLL1 FT7 cultures, we performed another experiment focused on sorted Lin^−^HLA-DR^+^ cells ([Figures 7](#fig7){ref-type="fig"}C, 7D, and 7F). Strikingly, two clusters were identified for each of the DC populations: C1 and C7 for cDC2s, C2 and C9 for pDCs, and C6 and C11 for cDC1s ([Figures 7](#fig7){ref-type="fig"}C, 7D, and 7F). The smallest of each of these cluster pairs encompassed cells expressing mitosis genes ([Figures 7](#fig7){ref-type="fig"}D and 7F), thus corresponding to pre-terminally differentiated cells equivalent to those identified in our SmartSeq2 experiment for cDC1s and in the bulk 10X Genomics experiment for pDCs but newly revealed for cDC2s. In conclusion, our OP9+OP9_DLL1 FT7 cultures encompassed prominent populations of hematopoietic progenitor cells engaged in lymphoid, myeloid, or erythroid differentiation, monocyte-derived cells, and the three major types of human DCs, including pre-terminal differentiation states of these cells expressing cell-cycle genes.Figure 7Unbiased Analysis of the Composition of OP9+OP9_DLL1 FT7 Cultures through Droplet-Based High-Throughput scRNAseq(A) scRNAseq-based identification of clusters of cell types or states from viable CD45^+^ cells from one culture using t-SNE with graphical clustering. 12 cell clusters were identified. The numbers of cells in each cluster are indicated in the graphical legend box, together with the percentages they represent out of the total cells analyzed.(B) Violin plots showing expression profiles of previously known cell-type-specific genes across all individual cells and in comparison between cell clusters.(C) Identification of clusters of cell types or states from sorted Lineage^−^HLA-DR^+^ cells. 13 cell clusters were identified.(D) Violin plots showing expression profiles of the same genes as in (B).(E and F) Expression patterns of 156 genes representative of those that were the most differentially expressed across cell clusters, as a heatmap with hierarchical clustering of cell clusters (columns) and genes (rows), for total live CD45^+^ cells (E) and enriched Lineage^−^HLA-DR^+^ cells (F). Genes clustered largely according to previously known co-expression in specific cell types, as highlighted by the vertical bars and their annotations on the right of each heatmap.See also [Figure S7](#mmc1){ref-type="supplementary-material"} and [Data S1](#mmc2){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

In our culture system, DLL1-dependent Notch inhibited human pDC development, consistent with a previous report ([@bib13]) but in contrast to another study claiming the opposite ([@bib34]). These discrepant results may be explained by different effects of Notch signaling depending on the DC developmental pathways. A recent study demonstrated a critical role of Notch signaling among the microenvironmental cues instructing the development of human HLA-DR^+^ CD13^+^ CD11c^+^ BDCA1^+^ DCs in the thymus, without specific investigation regarding the presence of cDC1s ([@bib30]). As compared to our protocol, the cell yields in this study were 50 times lower for pDCs and at least 10 times lower for cDCs. Hence, we demonstrated unequivocally that DLL1-dependent Notch signaling and GM-CSF cooperate to promote human cDC1 generation. Moreover, we developed a cell culture system yielding much higher numbers of human pDCs, cDC1s, and cDC2s than previously reported. Our results are consistent with those reported in an independent study that was conducted in parallel to ours and published very recently ([@bib22]).

cDC1s and pDCs share developmental dependence on the transcription factor IRF8. Constitutive loss of TCF4 expression in murine pDCs induces their upregulation of ID2 and their differentiation into cDC1-like cells ([@bib15]). Hence, bifurcation from the common DC progenitor between the pDC and cDC1 cell lineages is likely enforced by reciprocal and antagonistic expression of ID2 and TCF4. Notch2 receptor knockdown in murine CD11c^+^ splenocytes interferes with cDC2 and, to a lesser extent, cDC1 development, whereas pre-DC numbers are unaffected ([@bib27]). Mouse splenic cDC1s do not express Notch target genes ([@bib27]). Hence, Notch signaling likely promotes murine splenic cDC1 development at a precursor stage ([@bib27]). Combined with these observations in mice, our data on *in vitro* differentiation of human DC types strongly suggest an evolutionary conserved Notch-dependent lineage bifurcation between pDCs and cDC1s from their common precursor stage. Hence, we propose that Notch-dependent interactions between precursors and stromal cells contribute to instruct commitment into the human cDC1 lineage.

Phenotypic and functional characterization of *in-vitro*-derived cDC1s and pDCs confirmed their strong homology with their *in vivo* counterparts based on their shared expression of key cell-surface markers and the similarity of their phenotypic maturation and cytokine production upon TLR stimulations. CD11c expression was low on *in-vitro*-derived cDC1s, consistent with the lower levels of CD11c expression observed on human cDC1s as compared to cDC2s in blood, secondary lymphoid organs, and the parenchyma from non-lymphoid tissues ([@bib16]). Hence, to identify cDC1s *ex vivo* in tissues and *in vitro* in culture models, caution should be taken not to use too high a threshold for CD11c expression.

The identity of the DC types generated in our cultures and their strong homology to their blood counterparts were unambiguously demonstrated by scRNAseq analyses. Strikingly, heterogeneity was revealed in each DC type, with a minor cell cluster characterized by mitosis gene expression and lack of XCR1 but increased expression of CXCR4 in the case of cDC1s. These cells likely represent previously overlooked immediate precursors of terminally differentiated DCs. We confirmed at the protein level that CLEC9A^+^CADM1^+^ cDC1s split into XCR1^−^ and XCR1^+^ cells, with the first expressing higher levels of CXCR4. We also confirmed that XCR1^−^ cDC1s represent an immediate precursor of terminally differentiated XCR1^+^ cDC1s and can be found circulating in the blood. Thus, we demonstrated the power of scRNAseq to reveal overlooked differentiation states of human DC types. Further studies aiming at comparing the functions of XCR1^−^ versus XCR1^+^ cDC1s should help better understand the differentiation of this DC lineage and its coupling to the acquisition of functional specialization. In mice, there are two forms of splenic cDC1s (as reviewed in [@bib14]): a pre-cross-presentation stage and a later stage that has acquired the capacity to cross-present antigens (the latter ability being induced by GM-CSF and correlating with XCR1 expression; [@bib4]). It remains to be tested whether the human XCR1^−^ cDC1s identified in our study represent the counterparts of the mouse pre-cross-presentation cDC1 state.

In conclusion, we provide a valuable *in vitro* protocol to generate large numbers of pDCs, cDC1s, and cDC2s within the same culture of CD34^+^ cells. When combined with the inhibition of candidate regulators, through pharmacological or genetic manipulations, this culture system will allow experimental testing of the mechanisms controlling the differentiation or functions of human MNPs. Since our culture system encompasses hematopoietic progenitors engaged in differentiation toward multiple immune lineages, its further adaptation might enable terminal differentiation of additional cell types to facilitate studying their interactions with DCs. Different strategies are being pursued to harness DC types for innovative vaccines or immunotherapies against viral infections or cancer ([@bib40]). Therefore, our system will also be useful for translational applications, including *in vitro* drug and vaccine testing on DC types. Further deep characterization of cell cultures modeling the differentiation of human MNP, as achieved here, should also yield novel strategies to generate *in vitro* the best suited combinations of MNP types and states for adoptive cell transfer to boost anti-tumoral responses in cancer patients ([@bib5]) or to prevent graft rejection upon organ transplantation ([@bib32]).

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Mouse Anti human CD303, PerCP/Cy5.5 conjugate, Clone 201A, dilution 1:100BiolegendCat \# 354210Mouse Anti human CD303, APC conjugate, Clone 201A, dilution 1:100BiolegendCat \#354206Mouse Anti-Human CD272 (BTLA), PE-CF594 conjugate, Clone J168-540, dilution 1:100BD BioscienceCat \# 564801Chicken Anti human CADM1, Purified, Clone 3E1, dilution 1:1000MBLCat \# CM004-3Chicken Anti human CADM1, Biotin conjugate, Clone 3E1, dilution 1:1000MBLCat \# CM004-6Mouse anti-human CD1c, APC/Cy7 conjugate, Clone L161, dilution 1:100BiolegendCat \# 331520Mouse anti-human CD11c, V450 conjugate, Clone B-ly6), dilution 1:100BD BioscienceCat \# 655112Mouse Anti-Human CD123, PE-Cy7 conjugate, Clone 7G3, dilution 1:50BD BioscienceCat \# 560826Mouse Anti-Human CD123, BV605 conjugate, Clone 6H6, dilution 1:200BiolegendCat \# 306026Mouse Anti-Human CD14, BV786 conjugate, Clone M5E2, dilution 1:50BD BioscienceCat \# 563698Mouse Anti-Human CD14, FITC conjugate, Clone HCD14, dilution 1:200)BiolegendCat \# 325604Mouse Anti-Human CD206, BV421 conjugate, Clone 19.2, dilution 1:100BD BioscienceCat \# 564062Mouse Anti-Human CD206, APC-Cy7 conjugate, Clone 15-2, dilution 1:200BiolegendCat \# 321110Mouse Anti-Human CD206, AF700 conjugate, Clone 15-2, dilution 1:200BiolegendCat \# 321132Mouse Anti-Human CX3CR1, PE conjugate, Clone K0124E1, dilution 1:100BiolegendCat \# 355704Mouse Anti-Human Thrombomodulin/BDCA-3, APC conjugate, Clone 501733, dilution 1:30R&D systemCat \# FAB3947AMouse Anti-Human Thrombomodulin/BDCA-3, BV785 conjugate, Clone M80, dilution 1:100BiolegendCat \# 344116Mouse Anti-Human Thrombomodulin/BDCA-3, APC-Vio770 conjugate, Clone AD5-14H12, dilution 1:50Miltenyi BiotecCat \# 130-098-217Mouse Anti-Human CD45, PE conjugate, Clone HI30, dilution 1:100BD BioscienceCat \# 555483Mouse Antihuman CD45RA, BV 655 conjugate, Clone HI 100, dilution 1:200BiolegendCat \# 304136Mouse Anti-Human CD80, PE conjugate, Clone L307.4, dilution 1:100BD Bioscience,Cat \# 557227Mouse Anti-Human CD83, PE conjugate, Clone HB15e, dilution 1:100BD Bioscience,Cat \# 556855Mouse Anti-Human CD86, Alexa Fluor® 700 conjugate, Clone 2331 (FUN-1), dilution 1:100BD Bioscience,Cat \# 561124Mouse Anti-Human CLEC9A, APC conjugate, Clone 8F9, dilution 1:50Miltenyi Biotec,Cat \# 130-097-371Mouse Anti-Human CLEC9A, Vio blue conjugate, Clone 8F9, dilution 1:50Miltenyi BiotecCat \# 130-097-406Mouse Anti-Human CLEC9A, PE conjugate, Clone 8F9, dilution 1:200BiolegendCat \# 353804Mouse Anti-Human CXCR4, APC conjugate, Clone 12G5, dilution 1:50Miltenyi BiotecCat \# 130-098-357Hamster anti-mouse DLL1, PE conjugate, Clone HMD1-3, dilution 1:100BiolegendCat \# 128307Mouse Anti-Human HLA-DR, Alexa Fluor 700 conjugate, Clone LN3, dilution 1:100eBioscienceCat \# 56-9956-42Mouse Anti-Human HLA-DR, BV786 conjugate, Clone G46-6, dilution 1:100BD BioscienceCat \# 564041Mouse anti-Human IFN-α\[2b\], PE conjugate, Clone 7N4-1, dilution 1:20BD BioscienceCat \# 560097Mouse Anti-Human IL-12 (p40/p70), PE conjugate, Clone C11.5, dilution 1:20BD BioscienceCat \# 554575Mouse Anti-Human IL-29/IFN-lambda 1, unconjugated, Clone 247801, dilution 1:1000R&D SystemsCat \# MAB15981-100Mouse Anti-Human Lineage Cocktail 1 (CD3, CD14, CD16, CD19, CD20, CD56), FITC conjugates (Clones SK7, MΦP9 3G8, SJ25C1, L27, NCAM16.2), dilution 1:100BD BioscienceCat \# 340546Mouse anti-human CD172a/b, APC conjugate, Clone SE5A5, dilution 1:100BiolegendCat \# 323810Mouse Anti-Human TNF, Alexa Fluor® 700 conjugate, Clone MAb11, dilution 1:100BD BioscienceCat \# 561023Mouse anti-human XCR1, PE conjugate, Clone S15046E, dilution 1:200BiolegendCat \# 372604Mouse anti-human CD3, PE conjugate, Clone SK7, dilution 1:100BiolegendCat \# 344806**Biological Samples**CB CD34+ cellsABCell BioCat \# CD34-CT-CGCBHospital de la Conception, Marseille ([@bib6])N/ACBNYC blood centerN/APeripheral bloodNYC blood centerN/A**Chemicals, Peptides, and Recombinant Proteins**γ-secretase inhibitor XXI, compound E (DAPT- 5 μM)CalbiochemCat \# 565790-1MGDimethyl sulfoxideSigma AldrichCat \# D2650-100MLRecombinant human Flt3LPeprotechCat \# 300-19Recombinant human Flt3LR&D SystemsCat \# 308-FKN-025Recombinant human SCFPeprotechCat \# 300-07Recombinant human SCFR&D SystemsCat \# 255-SC-050Recombinant human IL-7PeprotechCat \# 200-07Recombinant human IL-7R&D SystemsCat \# 207-IL-025Recombinant human TPOPeprotechCat \# 300-18Recombinant human TPOR&D SystemsCat \# 288-TP-025Recombinant human GM-CSFPeprotechCat \# 300-03Annexin-V (Pacific blue conjugate)BiolegendCat \# 640918Propidium Iodide SolutionBiolegendCat \# 421301Annexin V Binding BufferBiolegendCat \# 422201Mouse Anti-Chicken IgA-FITCSouthernBiotechCat\# 8330-02APC/Fire 750 StreptavidinBiolegendCat\# 405250PE/Dazzle 594 StreptavidinBiolegendCat\# 405247Lipopolysacharide (Ultrapure LPS, Salmonella Minnesota)InvivogenCat \# tlrl-smlpsPoly(I:C) HMWInvivogenCat \# tlrl-picR848 (Resiquimod)InvivogenCat \# tlrl-r848Class A CpG oligonucleotide: ODN 2216InvivogenCat \# tlrl-2216Brefeldin ASigma AldrichCat \# B7651-5MGFBSBiowestCat \# S1820-500FBSBiowestCat \# S1620-500α-MEM glutamaxThermofisher scientificCat \# 32561-029α-MEM glutamaxThermofisher scientificCat \#32561102Sodium Pyruvate (100 mM)Thermofisher scientificCat \# 11360070Penicillin-Streptomycin(10,000 U/mL)Thermofisher scientificCat \# 151401632-Mercaptoethanol (50 mM)Thermofisher scientificCat \# 31350010Trypsin-EDTA (0.05%), phenol redThermofisher scientificCat \# 25300054LIVE/DEAD Fixable Aqua Dead Cell Stain KitThermofisher scientificCat \# L34957Ficoll-Paque PLUS density gradient mediaGE HealthcareCat \# 17144003**Critical Commercial Assays**EasySep Human Pan-DC Pre-Enrichment KitSTEMCELL technologiesCat \# 19251Pan-DC Enrichment Kit, humanMiltenyiCat \# 130-100-777Fixation/Permeabilization Solution KitBD BioscienceCat \# 554714CD34 MicroBead Kit UltraPureMiltenyi BiotecCat \# 130-100-453APEX Alexa Fluor 647 Antibody Labeling KitThermofisher scientificA10475TCLQIAGENCat \# 1031576beta-mercaptoethanolThermoFisher: Life technologiesCat \# 21985-023Agencourt RNA Clean XPBeckman-CoulterCat \# A63987Recombinant RNase InhibitorclontechCat \# 2313BdNTP (10 mM each)ThermoFisher: Life technologiesCat \# R0192Betaine (5 M)Sigma-AldrichCat \# B0300-5VLReverse Transcription DNA oligonucleotide primerIntegrated DNA Technologies (IDT)N/AAAG CAG TGG TAT CAA CGC AGA GTA CTT TTT TTT\
TTT TTT TTT TTT TTT TTT TTT TVNPCR oligonucleotide primerIDTN/AAAG CAG TGG TAT CAA CGC AGA GTSMARTER TSO (with LNA)ExiqonN/AAAGCAGTGGTATCAACGCAGAGTACATrGrG+GMagnesium chloride solutionSigma-AldrichCat \# M1028-10X1MLSuperScript® II Reverse TranscriptaseThermoFisher: Life technologiesCat \# 18064-071KAPA HiFi HotStart PCR ReadyMixKAPA BiosystemsCat \# KK2602Agencourt AMPure XPBeckman-CoulterCat \# A63881High Sensitivity DNA BioAnalyzer kitAgilentCat \# 5067-4626High Sensitivity DNA Qubit kitThermoFisher: Life technologiesCat \# Q32854Qubit assay tubesThermoFisher: Life technologiesCat \# Q32856TE buffer (500ml)TEKNOVACat \# T0228Ethanol (100%) VWR 89125-170VWR 89125-170Cat \# 89125-170NexteraXT Library preparation kitIlluminaCat \# FC-131-1096Nextera IndexingILLUMINACat \# FC-131-1002Chromium single cell 3′ library kit V210X GenomicsCat \# 120264Chromium single cell 3′ gel bead kit v210X GenomicsCat \# 120265Chromium i7 multiplex kit10X GenomicsCat \# 120262Chromium single cell A chip kit10X GenomicsCat \# 120236**Deposited Data**SmartSeq2 scRNAseq dataThis paperGEO: [GSE108546](ncbi-geo:GSE108546){#intref0015}10X scRNAseq data for total *in vitro* cultureThis paperGEO: [GSE115405](ncbi-geo:GSE115405){#intref0020}10X scRNAseq data for Lin- HLA-DR+ cells sorted from cultureThis paperGEO: [GSE115405](ncbi-geo:GSE115405){#intref0025}10X scRNAseq data for Lin- HLA-DR+ cells sorted from DC-enriched PBMCsThis paperGEO: [GSE115405](ncbi-geo:GSE115405){#intref0030}**Experimental Models: Cell Lines**Mouse: OP9([@bib23])N/AMouse: OP9-DL1([@bib42])N/A**Software and Algorithms**FCS express 6.04,De Novo Software<https://www.denovosoftware.com/site/Flow-RUO-Overview.shtml>FlowJo 9Tree Star Inc.<http://docs.flowjo.com/vx/faq/general-faq/tree-star-flowjo/>STAR aligner (v2.5.3a)([@bib12])<https://github.com/alexdobin/STAR>HTSeq (v0.9.1)([@bib3])<https://github.com/simon-anders/htseq>Seurat (v1.4.0.16)([@bib39])<https://github.com/satijalab/seurat>BubbleGUM (v1.3.19)([@bib45])<http://www.ciml.univ-mrs.fr/applications/BubbleGUM/index.html>C-MAP([@bib24])<https://github.com/cmap>MorpheusN/A<https://software.broadinstitute.org/morpheus/>GraphPad Prism 7Graphpad software<https://www.graphpad.com/scientific-software/prism/>

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Marc Dalod (<dalod@ciml.univ-mrs.fr>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Human studies {#sec4.3.1}

Human nontherapeutic-grade CB samples were collected from informed and consenting mothers at the Marseille University Hospital de la Conception birth clinic, obtained through the Marseille CB bank and used for CD34^+^ cell enrichment (\> 95%), as described ([@bib6]), or from the UCB (USA national CB program). Alternatively, already purified CB CD34^+^ cell were purchased from a properly licensed commercial company (ABCell Bio). PBMCs were prepared by Ficoll (GE Healthcare) gradient centrifugation from buffy coats received from EFS (Marseille) or New York blood center (Long island city, NY, USA). Non-mobilized adult blood CD34^+^ cells were isolated using the CD34 MicroBead Kit UltraPure (Miltenyi). Donor cells were negative for HBV, HCV, HIV1/2, bacteria, fungi, and mycoplasma.

### Cell lines {#sec4.3.2}

The OP9 ([@bib23]) and OP9-DLL1 ([@bib42]) cell lines were initially imported at CIML by Bernard and Marie Malissen, from the laboratory of Pr. Juan Carlos Zuniga-Pflücker, and provided to us through the laboratory of Pierre Ferrier (CIML).

Method Details {#sec4.4}
--------------

### Expansion and differentiation of CB precursors on OP9 stromal cell lines {#sec4.4.1}

Purified CD34^+^ human CB cells were thawed and expanded in 96 well round bottom plates (Falcon) at 25,000 cells/ml in α-MEM glutamax (Life Technologies), 10% FCS (Biowest), Penicillin / Streptomycin, 1mM sodium pyruvate, 50 μM β-mercaptoethanol, 25ng/ml hFLT3L, 5ng/ml hIL7, 5ng/ml hTPO, 2.5ng/ml hSCF, and for some experiments hGM-CSF (cytokines from Peprotech or R&D). Expansion was performed in 200 μL per well for 7 days at 5% CO~2~, +37°C. Expanded cells were either frozen for later use or directly differentiated. 24h before differentiation start, OP9 or OP9_DLL1 cells were harvested using 0.05% trypsin. 12,500 cells were seeded in 500 μL α-MEM, 20% FCS, Penicillin / Streptomycin, 1mM sodium pyruvate, 50 μM β-mercaptoethanol in a 24 well flat bottom plate (Falcon). In case of the mixed feeder layer, a 3:1 ratio of OP9 and OP9_DLL1 was used. The stromal cell layer was 70%--80% confluent on the day of the experiment. Before differentiation, the medium was gently replaced and the concentration of the expanded precursor cells was adjusted to 20,000 cells/ml. Cytokines were added v/v at a 2x concentration, to achieve final concentrations of 15ng/ml hFLT3L, 5ng/ml hIL7, and 2.5ng/ml hTPO, with eventual addition of hGM-CSF as described in the relevant Figures. In each well prepared with a stromal cell layer, 500ul of expanded precursor suspension was gently added. Cells were incubated for 14-21 days at 5% CO~2~, +37°C. On day7 and 14 of the differentiation, half of the medium was replaced by fresh one supplemented with cytokines. Cells were harvested by pipetting and filtered through a 30 μm nylon mesh, between days 14 and 21.

### Cell stimulations {#sec4.4.2}

Cell cultures were stimulated with medium, 5 μg/ml R848, 5 μg/ml CpG2216, 1 μg/ml LPS, 5 μg/ml poly(I:C), or 5 μg/ml R848 + 5 μg/ml HMW poly(I:C) (InvivoGen) directly in the 24 well plates used for differentiation. Half of the culture medium was replaced by fresh one supplemented with the TLR agonists and 200ng/ml hFLT3L, 50ng/ml hIL3 (Peprotech). Brefeldin A (Sigma) was added at a final concentration of 10 μg/ml after 2h (6h time point) or 14h (16h time point) of stimulation. For the analysis of activation markers, cells were stimulated for 16h without Brefeldin A.

### Flow cytometry {#sec4.4.3}

Cells were stained with the live dead fixable aqua dead kit (Invitrogen) and with the antibodies listed in the supplemental information. Intracellular staining were performed using the Fix/Perm kit (BD). Cells stained for cell surface markers were assessed for apoptosis by incubation with Annexin V for 30 min followed by addition of PI immediately before acquisition, without further washing. Samples were acquired on LSR II or Fortessa (BD) and analyzed with FlowJo (Tree Star) or FCS express 6.04, (*De Novo* Software) software. ViSNE analysis from compensated FCS files was performed using Cytobank.

### Inhibitor experiments {#sec4.4.4}

The γ-secretase inhibitor XXI, compound E (DAPT; Calbiochem), was used to block Notch signaling at a concentration of 5 μM. DMSO was used as control.

### Cell sorting {#sec4.4.5}

Cells were sorted on a FACSAria (BD biosciences). For SmartSeq2 scRNAseq, single cells were index sorted using the indicated gating strategy, from FT7 cultures differentiated on OP9+OP_DLL1 for 18 days. For the 10X Genomics scRNAseq experiments from cultures, cells were harvested by pipetting, filtered through a 30 μm nylon mesh, and sorted by flow cytometry as live (LIVE/DEAD Fixable Aqua Dead^-^) total hematopoietic (CD45^+^) or Lin^-^ HLA-DR^+^, using PE-CD45, or FITC-lineage cocktail (CD3, CD14, CD16, CD19, CD20, CD56) with BV786-HLA-DR, APC-BDCA2/CD303 and V450-CD11c, before loading into the Chromium Single Cell Controller apparatus. For the 10X Genomics scRNAseq experiment with cells enriched from adult PBMCs, cells from a healthy blood donor were separated by density gradient centrifugation, enriched by magnetic bead-based sorting using the pan-DC enrichment kit from Miltenyi, stained and sorted for Lin^-^ HLA-DR^+^ cells as done for the cells from cultures, before loading into the Chromium Single Cell Controller apparatus. Peripheral blood XCR1^-^ and XCR1^+^ cDC1 subsets were sorted from PBMCs enriched with the EasySep Human Pan-DC Pre-Enrichment Kit (stem cell technologies), by gating on Lin^-^ HLA-DR^+^ CD123^-^ CD45RA^-^ CD11c^+^ CD1c^-^ SIRPa^-^ CD141^+^ CLEC9A^+^ CADM1^+^ cells. Sorted cells were cultured for 14 days on OP9_DLL1 by plating 10,000 to 30,000 cells/ml with the FT7+G cytokine cocktail.

### Single-cell RNA sequencing {#sec4.4.6}

RNA purification and library generation for SmartSeq2 was performed as described ([@bib50]). For the droplet-based scRNAseq, sorted cell samples were processed by HalioDx testing laboratory, using the Chromium Single Cell Controller apparatus with the single cell 3′ Library, Gel beads & multiplex kit (10X Genomics, Pleasanton) as per the manufacturer protocol. Libraries were sequenced by 50-bp versus 75-bp paired-end reading on a High Seq 4000 versus NextSeq500 sequencer (Illumina) for SmartSeq2 versus 10X Genomics data respectively. Reads were aligned on the GRCh38 human genome assembly. Data analysis was performed using the R software package Seurat (<https://github.com/satijalab/seurat>) ([@bib39]).

### Single cell RNA-Seq data processing {#sec4.4.7}

For both SmartSeq2 and 10X Genomics data, sequencing reads were mapped to the human reference genome (GRCh38.87) using the STAR aligner (v2.5.3a) ([@bib12]) and read counts were generated using HTSeq (v0.9.1) ([@bib3]).

Count matrices were normalized and filtered using the Setup function of the Seurat (v1.4.0.16) package ([@bib39]) in the R environment (v3.4.1).

For SmartSeq2 data, cells with less than 5000 genes expressed at detectable levels and genes detected in less than 3 cells were filtered out; 86 cells and 18017 genes were retained and the corresponding data was log-transformed \[log(data+1)\] prior to further analysis.

For 10X Genomics data, cells with less than 200 genes expressed at detectable levels and genes detected in less than 3 cells were filtered out. The high-quality of the retained cells was confirmed by additional QC filters, based on the mitochondrial gene expression rate (cells in which more than 10% of total genes were mitochondrial genes were removed) and the read alignment rate. Overall, 2605 cells and 16495 genes from the total *in vitro* culture, 4462 cells and 17295 genes from the Lin-HLA-DR+ enriched culture and 5050 cells and 15107 genes from the PBMCs were kept for further analyses.

### Single cell RNA-Seq data analysis {#sec4.4.8}

Following the Seurat pipeline, highly-variable genes (HVGs) were first selected based on thresholds on average expression and dispersion z-score; this method allowed us to take into account the intrinsic relationship between the mean and the variance of the expression values of the genes across the cells. In order to reduce the dimensionality of the dataset, a principal component analysis (PCA) was performed, using as input the expression values of the HVGs across the cells. The highly contributing principal components (PCs) were identified through the jackstraw permutation test (1000 iterations for SmartSeq2 and 500 permutations for 10X Genomics data). Then, a proportion test is performed to assess, for each PC, the robustness of the association of each gene to this PC and the statistical significance of the difference between the distribution of the obtained p values and the uniform distribution. Cell loadings for the highly contributing PCs subsequently served as input to perform both t-distributed stochastic neighbor embedding (t-SNE; perplexity p = 10 for SmartSeq2 data, p = 80 for 10X PBMCs and Lin-HLA-DR+ enriched *in vitro* culture, p = 40 for 10X total culture) and graph-based clustering of the cells (k = 4; resolution = 0.6 for Smartseq2 data; k = 10, resol = 0.4 for 10X Lin-HLA-DR+ enriched culture, k = 10, r = 0.3 for 10X PBMCs, k = 15, r = 0.4 for 10X total culture); the obtained clusters were finally projected on top of the t-SNE plot, thus allowing to visualize the structure and the heterogeneity of the dataset in two dimensions. In brief, clustering relied on the superposition of two graphical clustering algorithms (K-Nearest Neighbors, performed using an Euclidean distance matrix as input, and Shared Nearest Neighbors) and of the Smart Local Moving (SLM) algorithm, aiming at optimizing the modularity of the clustering, which quantifies the ratio between intra-cluster connectivity and inter-cluster connectivity.

In order to identify putative markers for the clusters while keeping full benefit from the single-cell resolution of the data, we used the Receiver-Operating characteristic (ROC) statistical test, which quantifies the classification power of each individual gene between two clusters (or groups of clusters) through an AUC (Area Under the Curve) value.

C-MAP analysis was performed in R (v3.4.1) using an adaptation for single cells of the original R script, with the following parameters: 1000 permutations, ref = NULL, scaling = "none."

Hierarchical clustering and heatmaps were made with the Morpheus software (<https://software.broadinstitute.org/morpheus/>).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

High-throughput GSEA was performed using BubbleMap from the BubbleGUM (v1.3.19) suite ([@bib45]), with the default parameters except: permutation type = phenotype, Max geneset size = 5000, Min geneset size = 5.

The Prism software (GraphPad) was used for calculating statistics. Unless stated otherwise, statistical analyses were performed using Mann Whitney non parametric two tailed paired t test. Only statistically significant differences are shown. p \< 0.05; ^∗∗^, p \< 0.01.

Data and Software Availability {#sec4.6}
------------------------------

The accession numbers for the raw single cell RNA-sequencing data reported in this paper are GEO: [GSE108546](ncbi-geo:GSE108546){#intref0095} and [GSE115405](ncbi-geo:GSE115405){#intref0100}.
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